Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06563102 · ClinicalTrials.gov registry record · Phase 4
Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 101
- Enrollment target
NCT06563102 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 101 participants.
The verdict
NCT06563102, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 101 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of albuterol/budesonide to albuterol in changes in airway inflammation, asthma symptoms, and rescue therapy utilization in adults with mild asthma. Study details include: * The study duration will be up to 15 weeks. * The treatment duration will be 12 weeks. * The visit frequency will be once every 4 weeks, with 3 clinic visits and 2 video calls in total.
Interventions
- COMBINATION_PRODUCT Albuterol/Budesonide
- COMBINATION_PRODUCT Albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2026-02-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06563102
The ClinicalTrials.gov registry entry for NCT06563102 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Albuterol/Budesonide is the first listed.
NCT06563102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06563102 about?
NCT06563102 is a clinical study titled "Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma". The purpose of this study is to compare the efficacy and safety of albuterol/budesonide to albuterol in changes in airway inflammation, asthma symptoms, and rescue therapy utilization in adults with mild asthma. Study details include: * The study duration will be up to 15 weeks. * The treatment du...
What is the current status of trial NCT06563102?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 101 participants. The study started on 2024-09-11. Estimated completion is 2026-02-24.
What interventions are being tested in trial NCT06563102?
The interventions under investigation include: Albuterol/Budesonide (COMBINATION_PRODUCT), Albuterol (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06563102?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.